COVID-19 is an active, evolving and highly contagious disease caused by a new strain of coronavirus, SARS-CoV2. While around two per cent of people who get the flu in a typical season have severe or life-threatening complications requiring hospitalisation, around 10 per cent of COVID-19 cases result in life-threatening complications.

Here we answer why COVID-19 can be deadlier than the current flu viruses and how our researchers are tackling this disease.

What is coronavirus?

How did COVID-19 get it’s name?

How is COVID-19 spread?

Coronavirus symptoms, diagnosis and treatment

Our COVID-19 research

COVID-19 has highlighted how damaging out-of-control inflammation can be. Patients with severe COVID-19 develop out-of-control inflammation as their bodies try to fight the virus. This triggers a severe hyper-inflammatory response leading to acute respiratory distress syndrome (ARDS) and organ failure. Restricting this inflammatory response could help save lives.

Hudson Institute researchers are using their world-leading inflammation expertise to understand how this response happens and develop treatments to mitigate the deadly inflammation caused by COVID-19.

Tackling acute inflammation in COVID-19 and pathogenic influenza virus

Dr Michelle Tate and A/Prof Ashley Mansell from Centre for Innate Immunity and Infectious Diseases at Hudson Institute

By identifying the molecular mechanisms behind viral lung inflammation and how COVID-19 results in severe lung inflammation, the team will develop and test new and repurposed anti-inflammatory treatments for acute respiratory distress syndrome (ARDS) associated with severe COVID-19 and influenza virus infections.

Single gene disorder in the innate immune pathway in infectious and inflammatory disease

Cancer drug investigated for severe COVID-19 treatment

Using your immune system to fight COVID-19

COVID-19 collaborators

Support for people with COVID-19

Hudson Institute scientists cannot provide medical advice.
Find out more about COVID-19.

Share this page